GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Cyclically Adjusted Book per Share

Zealand Pharma A/S (LTS:0NZU) Cyclically Adjusted Book per Share : kr24.40 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zealand Pharma A/S's adjusted book value per share for the three months ended in Mar. 2024 was kr45.556. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr24.40 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Zealand Pharma A/S's average Cyclically Adjusted Book Growth Rate was 7.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Zealand Pharma A/S was 6.90% per year. The lowest was 4.40% per year. And the median was 5.65% per year.

As of today (2024-06-05), Zealand Pharma A/S's current stock price is kr615.25. Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr24.40. Zealand Pharma A/S's Cyclically Adjusted PB Ratio of today is 25.22.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma A/S was 31.77. The lowest was 3.30. And the median was 9.93.


Zealand Pharma A/S Cyclically Adjusted Book per Share Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted Book per Share Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.50 20.51 21.79 22.82 23.45

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.68 22.57 23.33 23.45 24.40

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=45.556/118.4000*118.4000
=45.556

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.229 99.700 15.710
201409 13.974 99.700 16.595
201412 11.173 99.400 13.309
201503 9.244 100.200 10.923
201506 7.103 100.300 8.385
201509 6.788 100.200 8.021
201512 10.603 99.800 12.579
201603 7.495 100.200 8.856
201606 4.486 100.600 5.280
201609 8.535 100.200 10.085
201612 10.876 100.300 12.839
201703 9.875 101.200 11.553
201706 7.084 101.200 8.288
201709 20.824 101.800 24.220
201712 16.772 101.300 19.603
201803 14.243 101.700 16.582
201806 10.305 102.300 11.927
201809 40.423 102.400 46.739
201812 36.334 102.100 42.135
201903 34.316 102.900 39.485
201906 30.449 102.900 35.036
201909 39.362 102.900 45.291
201912 33.167 102.900 38.163
202003 32.948 103.300 37.764
202006 45.299 103.200 51.971
202009 40.036 103.500 45.800
202012 30.887 103.400 35.368
202103 38.522 104.300 43.730
202106 31.848 105.000 35.912
202109 27.471 105.800 30.743
202112 21.469 106.600 23.845
202203 16.422 109.900 17.692
202206 10.951 113.600 11.414
202209 7.913 116.400 8.049
202212 15.852 115.900 16.194
202303 13.004 117.300 13.126
202306 29.649 116.400 30.158
202309 31.163 117.400 31.428
202312 27.285 116.700 27.682
202403 45.556 118.400 45.556

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Zealand Pharma A/S  (LTS:0NZU) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zealand Pharma A/S's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=615.25/24.4
=25.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma A/S was 31.77. The lowest was 3.30. And the median was 9.93.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zealand Pharma A/S Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (LTS:0NZU) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (LTS:0NZU) Headlines

No Headlines